Comparing Two Doses of Ipilimumab
Ahmad Tarhini, MD, PhD, associate professor, University of Pittsburgh School of Medicine, compares two doses of ipilimumab (Yervoy).
Ahmad Tarhini, MD, PhD, associate professor, University of Pittsburgh School of Medicine, compares two doses of ipilimumab (Yervoy).
<<<
Articles in this issue
Unprecedented Response Rates Seen With Ipilimumab Plus Nivolumab in Melanoma
Toxicity of Immunotherapies in Melanoma
Comparing Two Doses of Ipilimumab
New Standards Needed to Lessen Surgery Delays in Melanoma
Neoantigens for Personalized Immunotherapy May Boost Melanoma Treatment
Gene Removal May Pose Future Treatment in Advanced Melanoma
The Development of T-VEC for Melanoma
The Role of Macrophages in BRAF Inhibitor Resistance
Recent Videos
Related Content
